Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

REVB

Revelation Biosciences Inc

Last Close
Apr 26 • 11:34AM ET
2.24
Dollar change
+0.10
Percentage change
4.68 		%
Held by: VXF Scroll to Statements
Index- P/E0.07 EPS (ttm)30.60 Insider Own0.18% Shs Outstand1.63M Perf Week0.00%
Market Cap3.65M Forward P/E- EPS next Y-18.88 Insider Trans-90.44% Shs Float1.63M Perf Month-7.82%
Income-0.12M PEG- EPS next Q-5.38 Inst Own1.91% Short Float1.14% Perf Quarter-77.30%
Sales0.00M P/S- EPS this Y-3731.13% Inst Trans-76.10% Short Ratio0.05 Perf Half Y-88.15%
Book/sh25.13 P/B0.09 EPS next Y7.04% ROA-1.36% Short Interest0.02M Perf Year-93.09%
Cash/sh7.36 P/C0.30 EPS next 5Y- ROE-3.12% 52W Range1.78 - 39.00 Perf YTD-85.09%
Dividend Est.- P/FCF- EPS past 5Y- ROI-1.81% 52W High-94.26% Beta0.17
Dividend TTM- Quick Ratio2.17 Sales past 5Y0.00% Gross Margin- 52W Low25.84% ATR (14)0.28
Dividend Ex-Date- Current Ratio2.17 EPS Y/Y TTM107.59% Oper. Margin0.00% RSI (14)43.50 Volatility9.74% 11.08%
Employees9 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price32.12
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q-370.95% Payout- Rel Volume0.22 Prev Close2.14
Sales Surprise- EPS Surprise38.91% Sales Q/Q- EarningsMar 22 AMC Avg Volume400.26K Price2.24
SMA20-3.52% SMA50-16.72% SMA200-84.48% Trades Volume31,121 Change4.68%
Mar-22-24 09:52PM
REVB Stock Earnings: Revelation Biosciences Beats EPS for Q4 2023
(InvestorPlace)
04:15PM
Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023
(Business Wire)
Mar-13-24 09:00AM
Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024)
(Business Wire) -16.67%
Mar-12-24 09:00AM
Revelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth Conference
(Business Wire) -7.14%
Mar-04-24 09:00AM
Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini
(Business Wire) -6.32%
09:00AM Loading…
Feb-13-24 09:00AM
Revelation Biosciences Inc. Receives Invitation to Give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)
(Business Wire) +8.70%
Feb-05-24 04:41PM
Revelation Biosciences Inc. Announces Closing of $6.2 Million Public Offering
(Business Wire) +5.09%
Feb-01-24 08:27AM
Why Is Revelation Biosciences (REVB) Stock Down 62% Today?
(InvestorPlace) -63.86%
06:00AM
Revelation Biosciences Inc. Announces Pricing of $6.2 Million Public Offering
(Business Wire)
Jan-30-24 09:00AM
Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)
(Business Wire) -38.80%
Jan-29-24 08:26AM
Why Is Revelation Biosciences (REVB) Stock Up 61% Today?
(InvestorPlace) +31.66%
Jan-23-24 09:00AM
Revelation Biosciences Inc. Announces 1-for-30 Reverse Stock Split Effective January 25, 2024
(Business Wire) -21.38%
Nov-13-23 04:05PM
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2023
(Business Wire)
Oct-12-23 09:00AM
Gemini Induces Pharmacologic Activity and Related Physiologic Changes in Multiple Preclinical Studies
(Business Wire)
Oct-04-23 09:00AM
Revelation Biosciences, Inc. to Present at the 2023 ROTH Healthcare Opportunities Conference
(Business Wire)
09:00AM Loading…
Oct-02-23 09:00AM
Revelation Biosciences Inc. Announces Appointment of Lakhmir Chawla, M.D. to Board of Directors
(Business Wire)
Aug-14-23 07:36AM
REVB Reports Solid Balance Sheet and Remains on Track
(Zacks)
Aug-11-23 04:10PM
Revelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2023
(Business Wire)
Jun-29-23 09:00AM
REMINDER: Revelation Biosciences, Inc. Urges All Stockholders to Vote at the 2023 Annual Meeting of Stockholders
(Business Wire)
Jun-22-23 10:24AM
REVB: REVB Looks Attractive Ahead of Trials
(Zacks Small Cap Research)
Jun-12-23 04:15PM
Revelation Biosciences Inc. Announces Adjournment of 2023 Annual Meeting of Stockholders to July 7, 2023 and Additional Proposal
(Business Wire)
May-22-23 09:00AM
Revelation Biosciences Inc. Announces Financial Results for the Three Months Ended March 31, 2023 and Recent Corporate Progress
(Business Wire) +7.21%
Mar-30-23 05:42PM
Revelation Biosciences Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Recent Corporate Progress
(Business Wire)
Mar-13-23 09:00AM
Revelation Biosciences Inc. Appoints Dr. Julia Bohannon and Dr. Antonio Hernandez to Scientific Advisory Board
(Business Wire)
Mar-06-23 09:00AM
Revelation Biosciences Inc. to Participate in a Fireside Chat at the 35th Annual Roth Conference
(Business Wire)
Feb-13-23 04:20PM
Revelation Biosciences Inc. Announces Closing of $15.6 Million Public Offering
(Business Wire)
Feb-09-23 09:42AM
Revelation Biosciences Inc. Announces Pricing of $15.6 Million Public Offering
(Business Wire) -48.51%
Feb-07-23 09:00AM
Revelation Biosciences Inc. Announces Preclinical Biomarker Data Supporting Activity of REVTx-300
(Business Wire) -22.65%
Jan-31-23 12:00PM
Revelation Biosciences Inc. Announces 1-for-35 Reverse Stock Split effective February 1, 2023 and Results of Special Meeting of Stockholders
(Business Wire) +5.26%
Jan-10-23 09:00AM
Revelation Biosciences Inc. Announces Mandatory Unit Separation to Occur on January 13, 2023
(Business Wire)
09:00AM Loading…
Nov-18-22 09:00AM
Revelation Biosciences Inc. Announces Future Clinical Development Plans Based on Recent Biomarker Analysis and Significant Reduction in New Collagen Deposition (Fibrosis) in Preclinical Model
(Business Wire)
Nov-10-22 04:30PM
Revelation Biosciences Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2022 and Recent Corporate Progress
(Business Wire) +7.79%
Oct-25-22 11:13AM
Revelation Biosciences Inc. Announces Positive Results in Preclinical Model of Acute and Chronic Kidney Disease
(Business Wire) +64.60%
Oct-06-22 07:00AM
Revelation Biosciences Inc. and Vanderbilt University Enter Exclusive Worldwide License Agreement
(Business Wire) +14.44%
Aug-15-22 05:30PM
Revelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2022 and Recent Corporate Progress
(GlobeNewswire)
Jul-29-22 11:45AM
Revelation Biosciences Inc. Announces Closing of $5 Million Public Offering
(GlobeNewswire) -6.10%
Jul-26-22 08:15AM
Revelation Biosciences Inc. Announces Pricing of $5 Million Public Offering
(GlobeNewswire) -51.39%
Jul-22-22 06:30PM
Revelation Biosciences Inc. Announces Topline Data for Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis
(GlobeNewswire) -23.04%
Jul-14-22 09:00AM
Revelation Biosciences Inc. Completes Database Lock for its Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis
(GlobeNewswire) +16.10%
Jun-13-22 09:00AM
Revelation Biosciences Inc. Announces Completion of Dosing for a Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis
(GlobeNewswire) -12.73%
May-23-22 09:00AM
Revelation Biosciences Inc. Announces Safety Monitoring Committee Recommendation for Continuing Evaluation of REVTx-99b for the Treatment of Allergic Rhinitis
(GlobeNewswire)
May-16-22 04:01PM
Revelation Biosciences Inc. Announces Financial Results for the Three Months Ended March 31, 2022 and Recent Corporate Progress
(GlobeNewswire)
Apr-06-22 09:00AM
Revelation Biosciences Inc. Announces Conference Call to Provide a Corporate Update
(GlobeNewswire)
Mar-30-22 09:00AM
Revelation Biosciences Inc. Announces Primary Endpoint Analysis for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx-99a for the Prevention of H3N2 Influenza Infection
(GlobeNewswire) -38.32%
Mar-24-22 09:00AM
Revelation Biosciences Inc. Outlines Details on the Upcoming Data Analysis for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx 99a for the Prevention of H3N2 Influenza Infection
(GlobeNewswire) +11.94%
Mar-22-22 09:00AM
Revelation Biosciences Inc. to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC
(GlobeNewswire) +6.54%
Mar-15-22 09:00AM
Revelation Biosciences Inc. Announces Enrollment and Dosing Complete for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx 99 for the Prevention of H3N2 Influenza Infection
(GlobeNewswire) +22.55%
Mar-08-22 09:00AM
Revelation Biosciences Inc. to Present at the 34th Annual Roth Conference
(GlobeNewswire)
Feb-07-22 09:00AM
Revelation Biosciences Inc. to Present at 2022 BIO CEO & Investor Conference
(GlobeNewswire) +9.58%
Jan-24-22 08:00AM
Revelation Biosciences Raises $7.76 Million in Equity Financing
(GlobeNewswire) -19.15%
Jan-20-22 09:00AM
Revelation Biosciences Inc. Announces First Group of Patients Dosed in Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx-99 for the Prevention of H3N2 Influenza Infection
(GlobeNewswire) -18.50%
Jan-18-22 09:00AM
Revelation Biosciences Inc. Announces First Patient Enrolled and Dosed in Phase 1b Clinical Study of REVTx-99 for the Treatment of Allergic Rhinitis
(GlobeNewswire) -27.25%
Jan-13-22 01:54PM
REPEAT -- Revelation Biosciences Inc. Announces Data Demonstrating REVTx-99 In Vitro Anti-Viral Activity Against SARS-CoV-2; Commencement of Trading as a Public Company
(GlobeNewswire) -19.03%
Revelation Biosciences, Inc. is a clinical-stage life sciences company, which focuses on the development of immunologic-based therapies for the prevention and treatment of disease. Its product candidates include REVTx-99b, its lead therapeutic candidate being developed for allergic rhinitis and chronic nasal congestion, REVDx 501, a rapid home use diagnostic that can be used to detect any respiratory viral infection, regardless of virus type or strain, without the need for specialized instrumentation, and REVTx 200, an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. The company was founded on November 20, 2019 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
TIDMARSH GEORGE FDirectorDec 08 '23Sale0.5227,77114,4380Dec 12 04:48 PM
TIDMARSH GEORGE FDirectorOct 16 '23Sale0.6610,9577,24342,096Oct 17 04:12 PM
TIDMARSH GEORGE FDirectorOct 16 '23Sale0.651,8451,19927,771Oct 18 05:15 PM
TIDMARSH GEORGE FDirectorSep 28 '23Sale0.691,42998642,096Oct 02 04:09 PM
TIDMARSH GEORGE FDirectorSep 18 '23Sale0.744,0002,96039,348Sep 18 05:18 PM
TIDMARSH GEORGE FDirectorSep 15 '23Sale0.739,5006,93543,348Sep 18 05:18 PM
TIDMARSH GEORGE FDirectorSep 14 '23Sale0.7512,0009,00052,848Sep 18 05:18 PM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.